Radiotherapy as a New Player in Immuno-Oncology
Recent development in radiation biology has revealed potent immunogenic properties of radiotherapy in cancer treatments. However, antitumor immune effects of radiotherapy are limited by the concomitant induction of radiation-dependent immunosuppressive effects. In the growing era of immunotherapy, c...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315809/ https://www.ncbi.nlm.nih.gov/pubmed/30558196 http://dx.doi.org/10.3390/cancers10120515 |
_version_ | 1783384382639177728 |
---|---|
author | Wang, Shang-Jui Haffty, Bruce |
author_facet | Wang, Shang-Jui Haffty, Bruce |
author_sort | Wang, Shang-Jui |
collection | PubMed |
description | Recent development in radiation biology has revealed potent immunogenic properties of radiotherapy in cancer treatments. However, antitumor immune effects of radiotherapy are limited by the concomitant induction of radiation-dependent immunosuppressive effects. In the growing era of immunotherapy, combining radiotherapy with immunomodulating agents has demonstrated enhancement of radiation-induced antitumor immune activation that correlated with improved treatment outcomes. Yet, how to optimally deliver combination therapy regarding dose-fractionation and timing of radiotherapy is largely unknown. Future prospective testing to fine-tune this promising combination of radiotherapy and immunotherapy is warranted. |
format | Online Article Text |
id | pubmed-6315809 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63158092019-01-09 Radiotherapy as a New Player in Immuno-Oncology Wang, Shang-Jui Haffty, Bruce Cancers (Basel) Review Recent development in radiation biology has revealed potent immunogenic properties of radiotherapy in cancer treatments. However, antitumor immune effects of radiotherapy are limited by the concomitant induction of radiation-dependent immunosuppressive effects. In the growing era of immunotherapy, combining radiotherapy with immunomodulating agents has demonstrated enhancement of radiation-induced antitumor immune activation that correlated with improved treatment outcomes. Yet, how to optimally deliver combination therapy regarding dose-fractionation and timing of radiotherapy is largely unknown. Future prospective testing to fine-tune this promising combination of radiotherapy and immunotherapy is warranted. MDPI 2018-12-14 /pmc/articles/PMC6315809/ /pubmed/30558196 http://dx.doi.org/10.3390/cancers10120515 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wang, Shang-Jui Haffty, Bruce Radiotherapy as a New Player in Immuno-Oncology |
title | Radiotherapy as a New Player in Immuno-Oncology |
title_full | Radiotherapy as a New Player in Immuno-Oncology |
title_fullStr | Radiotherapy as a New Player in Immuno-Oncology |
title_full_unstemmed | Radiotherapy as a New Player in Immuno-Oncology |
title_short | Radiotherapy as a New Player in Immuno-Oncology |
title_sort | radiotherapy as a new player in immuno-oncology |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315809/ https://www.ncbi.nlm.nih.gov/pubmed/30558196 http://dx.doi.org/10.3390/cancers10120515 |
work_keys_str_mv | AT wangshangjui radiotherapyasanewplayerinimmunooncology AT hafftybruce radiotherapyasanewplayerinimmunooncology |